Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 354

1.

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.

James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L.

Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003.

PMID:
19332184
[PubMed - indexed for MEDLINE]
2.

Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J.

Med Sci Monit. 2009 Dec;15(12):MS24-30. Review.

PMID:
19946242
[PubMed - indexed for MEDLINE]
3.

Optimizing platelet P2Y12 inhibition for patients undergoing PCI.

Steinhubl S, Roe MT.

Cardiovasc Drug Rev. 2007 Summer;25(2):188-203. Review. Erratum in: Cardiovasc Drug Rev. 2007 Autumn;25(3):299.

PMID:
17614940
[PubMed - indexed for MEDLINE]
4.

Ticagrelor: a novel reversible oral antiplatelet agent.

Nawarskas JJ, Clark SM.

Cardiol Rev. 2011 Mar-Apr;19(2):95-100. doi: 10.1097/CRD.0b013e3182099d86. Review.

PMID:
21285670
[PubMed - indexed for MEDLINE]
5.

Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents.

Husted S.

Fundam Clin Pharmacol. 2009 Feb;23(1):1-9. doi: 10.1111/j.1472-8206.2008.00660.x. Review.

PMID:
19267766
[PubMed - indexed for MEDLINE]
6.

Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.

Anderson SD, Shah NK, Yim J, Epstein BJ.

Ann Pharmacother. 2010 Mar;44(3):524-37. doi: 10.1345/aph.1M548. Epub 2010 Feb 2. Review.

PMID:
20124464
[PubMed - indexed for MEDLINE]
7.

Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.

Husted S.

Postgrad Med. 2011 Nov;123(6):79-90. doi: 10.3810/pgm.2011.11.2498. Review.

PMID:
22104457
[PubMed - indexed for MEDLINE]
8.

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Motovska Z, Kala P.

Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Review.

PMID:
19281914
[PubMed - indexed for MEDLINE]
9.

Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.

Abergel E, Nikolsky E.

Vasc Health Risk Manag. 2010 Oct 21;6:963-77. doi: 10.2147/VHRM.S13263. Review.

PMID:
21057581
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Critical review of prasugrel for formulary decision makers.

Schafer JA, Kjesbo NK, Gleason PP.

J Manag Care Pharm. 2009 May;15(4):335-43. Review.

PMID:
19422273
[PubMed - indexed for MEDLINE]
Free Article
11.

Ticagrelor: a review of its use in the management of acute coronary syndromes.

Deeks ED.

Drugs. 2011 May 7;71(7):909-33. doi: 10.2165/11206850-000000000-00000. Review.

PMID:
21568367
[PubMed - indexed for MEDLINE]
12.

Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.

Mehta SR, Yusuf S.

J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):79S-88S. Review.

PMID:
12644345
[PubMed - indexed for MEDLINE]
Free Article
13.

Review of prasugrel for the secondary prevention of atherothrombosis.

Spinler SA, Rees C.

J Manag Care Pharm. 2009 Jun;15(5):383-95. Review.

PMID:
19496635
[PubMed - indexed for MEDLINE]
Free Article
14.

Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.

Teng R.

Clin Pharmacokinet. 2012 May 1;51(5):305-18. doi: 10.2165/11630960-000000000-00000. Review.

PMID:
22489610
[PubMed - indexed for MEDLINE]
15.

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

Mousa SA, Jeske WP, Fareed J.

Clin Appl Thromb Hemost. 2010 Apr;16(2):170-6. doi: 10.1177/1076029609355589. Review.

PMID:
20299391
[PubMed - indexed for MEDLINE]
16.

Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?

Silva MA, Donovan JL, Gandhi PJ, Volturo GA.

Vasc Health Risk Manag. 2006;2(1):39-48. Review.

PMID:
17319468
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.

Baker WL, White CM.

Am J Cardiovasc Drugs. 2009;9(4):213-29. doi: 10.2165/1131209-000000000-00000. Review.

PMID:
19655817
[PubMed - indexed for MEDLINE]
18.

Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.

Savi P, Herbert JM.

Semin Thromb Hemost. 2005 Apr;31(2):174-83. Review.

PMID:
15852221
[PubMed - indexed for MEDLINE]
19.

Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.

Thomas D, Giugliano RP.

Crit Pathw Cardiol. 2009 Mar;8(1):12-9. doi: 10.1097/HPC.0b013e318196bb46. Review.

PMID:
19258833
[PubMed - indexed for MEDLINE]
20.

Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.

Husted S, van Giezen JJ.

Cardiovasc Ther. 2009 Winter;27(4):259-74. doi: 10.1111/j.1755-5922.2009.00096.x. Review.

PMID:
19604248
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk